A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke

ClinicalTrials.gov ID: NCT00073476

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT00073476. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 15, 2026, 1:22 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Double-Blind, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy and Safety of a 72-Hour Infusion of CP-101,606 in Subjects With Acute Ischemic Stroke.

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

The purpose of this study is to determine whether a new research medication is effective and safe for the treatment of acute stroke when given within 6 hours of the onset of stroke.

Study identification

NCT ID: NCT00073476
Recruitment status: Terminated
Study type: Interventional
Phase: Phase 2
Lead sponsor: Pfizer; Industry
Enrollment: 300 participants

Conditions and interventions

Conditions

Stroke

Interventions

traxiprodil (CP-101,606) Drug

Drug

Eligibility (public fields only)

Age range: 40 Years to 90 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Sep 2003 (Type not available)
Primary completion: Not listed
Completion: Feb 2005 (Type not available)
Last update posted: Jun 22, 2006

2003 – 2005

United States locations

U.S. sites: 12
U.S. states: 7
U.S. cities: 8

Facility	City	State	ZIP	Site status
Pfizer Investigational Site	La Mesa	California	91942	—
Pfizer Investigational Site	Atlanta	Georgia	30342	—
Pfizer Investigational Site	Fort Wayne	Indiana	46804	—
Pfizer Investigational Site	Fort Wayne	Indiana	46805	—
Pfizer Investigational Site	Louisville	Kentucky	40202	—
Pfizer Investigational Site	Salisbury	North Carolina	28144	—
Pfizer Investigational Site	Dayton	Ohio	45406	—
Pfizer Investigational Site	Dayton	Ohio	45408	—
Pfizer Investigational Site	Dayton	Ohio	45409	—
Pfizer Investigational Site	Dayton	Ohio	45415	—
Pfizer Investigational Site	Allentown	Pennsylvania	18103	—
Pfizer Investigational Site	Philadelphia	Pennsylvania	19141	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 17 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00073476, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 22, 2006 · Synced Nov 15, 2026